256 related articles for article (PubMed ID: 10722049)
1. Engineering, purification and applications of His-tagged recombinant antibody fragments with specificity for the major birch pollen allergen, bet v1.
Flicker S; Laffer S; Steinberger P; Alhani B; Zhu Y; Laukkanen ML; Keinänen K; Kraft D; Valenta R
Biol Chem; 2000 Jan; 381(1):39-47. PubMed ID: 10722049
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of Bip 1, a monoclonal antibody that modulates IgE binding to birch pollen allergen, Bet v 1.
Laffer S; Vangelista L; Steinberger P; Kraft D; Pastore A; Valenta R
J Immunol; 1996 Dec; 157(11):4953-62. PubMed ID: 8943401
[TBL] [Abstract][Full Text] [Related]
3. High-level expression and purification of the major birch pollen allergen, Bet v 1.
Hoffmann-Sommergruber K; Susani M; Ferreira F; Jertschin P; Ahorn H; Steiner R; Kraft D; Scheiner O; Breiteneder H
Protein Expr Purif; 1997 Feb; 9(1):33-9. PubMed ID: 9116499
[TBL] [Abstract][Full Text] [Related]
4. Molecular cloning and characterization of a birch pollen minor allergen, Bet v 5, belonging to a family of isoflavone reductase-related proteins.
Karamloo F; Schmitz N; Scheurer S; Foetisch K; Hoffmann A; Haustein D; Vieths S
J Allergy Clin Immunol; 1999 Nov; 104(5):991-9. PubMed ID: 10550744
[TBL] [Abstract][Full Text] [Related]
5. Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations.
Niederberger V; Pauli G; Grönlund H; Fröschl R; Rumpold H; Kraft D; Valenta R; Spitzauer S
J Allergy Clin Immunol; 1998 Oct; 102(4 Pt 1):579-91. PubMed ID: 9802365
[TBL] [Abstract][Full Text] [Related]
6. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen.
Hochreiter R; Stepanoska T; Ferreira F; Valenta R; Vrtala S; Thalhamer J; Hartl A
Eur J Immunol; 2003 Jun; 33(6):1667-76. PubMed ID: 12778485
[TBL] [Abstract][Full Text] [Related]
7. A sensitive assay for the detection of IgE bound to the major birch pollen allergen, Bet v 1, in the form of immune complexes.
Pree I; Reisinger J; Bohle B; Frantal S; Valenta R; Niederberger V
J Immunol Methods; 2009 Jun; 345(1-2):100-5. PubMed ID: 19376122
[TBL] [Abstract][Full Text] [Related]
8. Expression of a human IgG4 antibody, BAB2, with specificity for the major Birch pollen allergen, Bet v 1 in Escherichia coli: recombinant BAB2 Fabs enhance the allergic reaction.
Eibensteiner P; Denépoux S; Steinberger P; Kraft D; Visco V; Banchereau J; Lebecque S; Valenta R
Int Arch Allergy Immunol; 1999; 118(2-4):190-2. PubMed ID: 10224374
[TBL] [Abstract][Full Text] [Related]
9. Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1.
Gieras A; Cejka P; Blatt K; Focke-Tejkl M; Linhart B; Flicker S; Stoecklinger A; Marth K; Drescher A; Thalhamer J; Valent P; Majdic O; Valenta R
J Immunol; 2011 May; 186(9):5333-44. PubMed ID: 21451110
[TBL] [Abstract][Full Text] [Related]
10. Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy.
Batard T; Didierlaurent A; Chabre H; Mothes N; Bussières L; Bohle B; Couret MN; Ball T; Lemoine P; Focks Tejkl M; Chenal A; Clément G; Dupont F; Valent P; Krauth MT; André C; Valenta R; Moingeon P
Int Arch Allergy Immunol; 2005 Mar; 136(3):239-49. PubMed ID: 15722633
[TBL] [Abstract][Full Text] [Related]
11. An in vitro model for the allergen-IgE-FcARI interaction.
Laffer S; Hogbom E; Adrianson J; Grönlund H; Sillaber C; Valent P; Vangelista L; Kricek F; Kraft D; Valenta R
Int Arch Allergy Immunol; 1999; 118(2-4):116-8. PubMed ID: 10224355
[TBL] [Abstract][Full Text] [Related]
12. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
Vrtala S; Akdis CA; Budak F; Akdis M; Blaser K; Kraft D; Valenta R
J Immunol; 2000 Dec; 165(11):6653-9. PubMed ID: 11086111
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization, expression in Escherichia coli, and epitope analysis of a two EF-hand calcium-binding birch pollen allergen, Bet v 4.
Twardosz A; Hayek B; Seiberler S; Vangelista L; Elfman L; Grönlund H; Kraft D; Valenta R
Biochem Biophys Res Commun; 1997 Oct; 239(1):197-204. PubMed ID: 9345295
[TBL] [Abstract][Full Text] [Related]
14. Rapid production of the major birch pollen allergen Bet v 1 in Nicotiana benthamiana plants and its immunological in vitro and in vivo characterization.
Krebitz M; Wiedermann U; Essl D; Steinkellner H; Wagner B; Turpen TH; Ebner C; Scheiner O; Breiteneder H
FASEB J; 2000 Jul; 14(10):1279-88. PubMed ID: 10877820
[TBL] [Abstract][Full Text] [Related]
15. Molecular composition and biological activity of commercial birch pollen allergen extracts.
Focke M; Marth K; Valenta R
Eur J Clin Invest; 2009 May; 39(5):429-36. PubMed ID: 19302561
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the T cell response to the major hazelnut allergen, Cor a 1.04: evidence for a relevant T cell epitope not cross-reactive with homologous pollen allergens.
Bohle B; Radakovics A; Lüttkopf D; Jahn-Schmid B; Vieths S; Ebner C
Clin Exp Allergy; 2005 Oct; 35(10):1392-9. PubMed ID: 16238801
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of recombinant T1, a non-allergenic periwinkle (Catharanthus roseus) protein, with sequence similarity to the Bet v 1 plant allergen family.
Laffer S; Hamdi S; Lupinek C; Sperr WR; Valent P; Verdino P; Keller W; Grote M; Hoffmann-Sommergruber K; Scheiner O; Kraft D; Rideau M; Valenta R
Biochem J; 2003 Jul; 373(Pt 1):261-9. PubMed ID: 12656672
[TBL] [Abstract][Full Text] [Related]
19. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
[TBL] [Abstract][Full Text] [Related]
20. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1.
Mahler V; Vrtala S; Kuss O; Diepgen TL; Suck R; Cromwell O; Fiebig H; Hartl A; Thalhamer J; Schuler G; Kraft D; Valenta R
Clin Exp Allergy; 2004 Jan; 34(1):115-22. PubMed ID: 14720271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
